TACI antibody (PE)
Quick Overview for TACI antibody (PE) (ABIN2663249)
Target
See all TACI (TNFRSF13B) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purification
- The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.
-
Isotype
- IgG2a kappa
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Protect from prolonged exposure to light. Do not freeze.
-
Storage
- 4 °C
-
Storage Comment
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
-
- TACI (TNFRSF13B) (Tumor Necrosis Factor Receptor Superfamily, Member 13B (TNFRSF13B))
-
Alternative Name
- CD267
-
Background
- TACI, Transmembrane Activator CAML (calcium modulator and cyclophilin ligand) Interactor, is a 32 kD type III transmembrane protein. It belongs to TNF receptor superfamily, known as TNFRSF member 13B (TNFRSF13B) or CD267. TACI is expressed on B cells, and myeloma cells. TACI contains 2 cysteine-rich domains (CRDs). Recent studies, however, have shown that another shorter form (TACI_d2) of TACI exists wherein the N-terminal CRD is removed by alternative splicing. TACI_d2 contains full affinity for its ligands. Several proteins (BAFF/BLys, APRIL, Syndecan-2) have been identified as TACI ligands. The interaction of TACI with its ligands induces activation of the transcription factors NFAT, AP1, and NF-κ B and plays a crucial role in humoral immunity by negative regulation of B cell proliferation and survival.
Target
-